Physiomics Regulatory News (PYC)

9 April 2021

Physiomics plc

("Physiomics") or ("the Company")

Conference presentation

Physiomics to present on Personalized Medicine and Virtual Tumour at AACR 2021 Annual Meeting

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Academy of Cancer Research ("AACR") Annual Meeting 2021, being held as a virtual event.

The Company will be presenting two original posters in the session "PO.BSB02.03.- Mathematical Modelling", scheduled for 10 April 2021 at 8.30 a.m. - 11.59 p.m. EDT (Eastern Daylight Time). The posters are titled:

· "A precision dosing application for patients treated with docetaxel and G-CSF" (Abstract #228) and

· "The abscopal effect: modelling and predicting the effect of radiation therapy on non-irradiated tumour when combined with immune checkpoint blockers" (Abstract #232)

The session will include live interactions and the posters will remain available for viewing by registered attendees until Monday the 21st of June 2021.

As previously disclosed, the Company is developing a personalised dosing tool to support clinician decision making on dosing of docetaxel in prostate cancer. The precision dosing poster describes additional functionality that has been incorporated to model the co-administration of G-CSF (a prophylactic treatment for neutropenia). This new functionality should increase the utility of the tool during the current COVID-19 pandemic when G-CSF is being more commonly administered than previously.

The second poster describes an update to the Company's Virtual Tumour™ model, enabling the simulation of the effects of radiotherapy not only on the irradiated tumour but other distant tumours (the "abscopal effect"). The abscopal effect is mainly driven by the activation of the immune systems and we illustrate how it can be synergistic with immune checkpoint blockers.

Copies of the posters will be made available on Physiomics' website at 8.30 a.m. EDT (1.30 p.m. BST) on 10 April 2021 at: https://www.physiomics.co.uk/resources.

According to AACR, it is the oldest and largest scientific organisation in the world, focused on every aspect of high-quality, innovative cancer research. Its annual conference is usually attended by representatives from public and private sector organisations, from the very small to the largest global players, with over 20,000 participants attending in 2019 (the last in-person meeting). This year, as a virtual event, access will be free to everyone who registers, and presentations may therefore reach a wider audience than usual.

More information about the conference may be found using the following link: https://www.aacr.org/meeting/aacr-annual-meeting-2021/

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.